Carnegie Investment Bank Norway wishes to congratulate Ultimovacs on the NOK 270 million private placement completed on 27 October 2021.
Ultimovacs intends to use the net proceeds from the private placement for the following purposes: (i) financing of the LUNGVAC Phase II trial evaluating UV1 in non-small cell lung cancer (“NSCLC”), (ii) bringing the UV1 platform into Phase III readiness, (iii) further development of the Tetanus-Epitope-Targeting (“TET”) technology platform, and (iv) general corporate purposes.
Carnegie is proud to have acted as joint bookrunner in the private placement and congratulates Carlos de Sousa, Hans Vassgård Eid and the rest of the Ultimovacs team with a successful transaction and we look forward to continuing our support of Ultimovacs going forward.